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MaOBJECTIVES The purpose of this study was to investigate the effects of enhancing gap junction (GJ) coupling during
acute myocardial infarction (MI) on the healed infarct scar morphology and late post-MI arrhythmia susceptibility.
BACKGROUND Increased heterogeneity of myocardial scarring after MI is associated with greater arrhythmia
susceptibility. We hypothesized that short-term enhancement of GJ coupling during acute MI can produce more
homogeneous infarct scars, reducing late susceptibility to post-MI arrhythmias.
METHODS Following arrhythmic characterization of a rat 4-week post-MI model (n ¼ 24), another 27 Sprague-Dawley
rats were randomized to receive rotigaptide to enhance GJ coupling (n ¼ 13) or to saline control (n ¼ 14) by osmotic
minipump immediately prior to and for the ﬁrst 7 days following surgically induced MI. At 4 weeks post-MI, hearts were
explanted for ex vivo programmed electrical stimulation (PES) and optical mapping. Heterogeneity of infarct border zone
(IBZ) scarring was quantiﬁed by histomorphometry.
RESULTS Despite no detectable differences in infarct size at 4 weeks post-MI, rotigaptide-treated hearts had reduced
arrhythmia susceptibility during PES (inducibility score for rotigaptide: 2.4 0.8; for control: 5.0 0.6; p¼ 0.02) and less
heterogeneous IBZ scarring (dispersion of IBZ complexity score: rotigaptide: 1.1  0.1; control: 1.4  0.1; p ¼ 0.04), asso-
ciated with an improvement in IBZ conduction velocity (rotigaptide: 43.1  3.4 cm/s; control: 34.8  2.0 cm/s; p ¼ 0.04).
CONCLUSIONS Enhancement of GJ coupling for only 7 days at the time of acute MI produced more homogeneous
IBZ scarring and reduced arrhythmia susceptibility at 4 weeks post-MI. Short-term GJ modulation at the time of MI may
represent a novel treatment strategy to modify the healed infarct scar morphology and reduce late post-MI
arrhythmic risk. (J Am Coll Cardiol EP 2016;2:574–82) © 2016 The Authors. Published by Elsevier on behalf
of the American College of Cardiology Foundation. This is an open access article under the CC BY license
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AB BR E V I A T I O N S
AND ACRONYM S
CV = conduction velocity
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575ventricular tachycardia (VT) (4–6). Therapeutic strate-
gies to homogenize infarct scarring, both by ablation
or pharmacologically, have been shown to be antiar-
rhythmic in the chronically infarcted heart (7–9).SEE PAGE 583
Cx43 = connexin43
GJ = gap junction
IBZ = infarct border zone
MI = myocardial infarction
PBS = phosphate-buffered
saline
PES = programmed electrical
stimulation
VT = ventricular tachycardiaGap junctions (GJs) are clusters of transmembrane
channels that mediate coupling of the cytoplasmic
compartments of adjacent cells and allow cell-to-cell
transfer of ions and small molecules. Studies have
shown that modulating GJ coupling can modify
intercellular passage of products of cell necrosis,
affect infarct spread, and may have small effects on
the size of the healed infarct (10–12). Enhancing GJ
coupling during MI at a time when natural GJ
uncoupling occurs (13) would be expected to increase
gap junctional exchange of chemical mediators of cell
death and survival between healthy and dying cells at
the ischemic border, thus homogenizing the distri-
bution of cell death and survival during MI. Although
any resulting myocardial salvage may be inadequate
to signiﬁcantly alter myocardial mechanical function,
even subtle alterations of the morphology of the scar
border relating to increased homogeneity of scarring
in the healed infarct may have important effects on
late post-MI arrhythmia susceptibility.
We hypothesized that enhancing GJ coupling only
for a limited duration at the time of MI, could
reduce late arrhythmia susceptibility in a chronically
infarcted heart, resulting from greater homogeneity
of scarring in the healed infarct. We characterized the
arrhythmic behavior and electrophysiology in a rat
model of healed MI and investigated the effects of
short-term GJ enhancement during acute MI on the
morphology and arrhythmia susceptibility of the
healed infarct scar.
METHODS
Methods are described brieﬂy here. For full details,
please see the Online Appendix.
ETHICAL APPROVAL. This work was performed in
accordance with standards set out in the United
Kingdom Animals (Scientiﬁc Procedures) Act 1986
and was approved by Imperial College London Ethical
Review Board and carried out under Project License
PPL 70/7033.
EXPERIMENTAL PROTOCOLS. To characterize the
arrhythmic behavior and electrophysiology of our 4-
week chronic MI model, 24 male Sprague-Dawley rats
(250 to 300 g) were subjected to surgical MI by
left anterior descending (LAD) artery ligation as pre-
viously described (14), while 4 rats underwent shamMI surgery. After 4 weeks of healing, rats
were sacriﬁced, and hearts were explanted,
perfused ex vivo, and subjected to optical
mapping of transmembrane voltage as previ-
ously described (15) and to programmed
electrical stimulation (PES) to provoke ven-
tricular arrhythmia.
To assess the effects of short-term GJ
modulation during acute MI on the healed
infarct morphology and arrhythmia suscepti-
bility at the chronic healed MI phase, another
27 rats were randomly allocated to 1 of 2
groups receiving 7 days of either rotigaptide
to enhance GJ coupling (n ¼ 13) or phosphate-
buffered saline (PBS) as the control group (n ¼ 14).
We had previously conﬁrmed that rotigaptide en-
hances GJ coupling in ventricular myocardium in the
context of acute ischemia/metabolic stress in sepa-
rate immunoblotting and ex vivo optical mapping
experiments (described in Online Appendix), consis-
tent with previously published studies (16).
Animals were given a bolus of GJ modulator or
vehicle subcutaneously immediately before LAD liga-
tion (2.5 nmol/kg rotigaptide or 0.5 ml of PBS). GJ
modulator or vehicle was then delivered for the ﬁrst
7 days post-MI, using intraperitoneal osmotic mini-
pumps (infusion rate of rotigaptide: 0.11 nmol/kg/min;
or PBS: 2 ml/week) (10). At 4 weeks post-MI (i.e., 3
weeks after discontinuation of rotigaptide admin-
istration), hearts were explanted for ex vivo optical
mapping with arrhythmia provocation studies
(PES). The vulnerability of hearts to PES-induced
arrhythmias was quantiﬁed using a previously
described and previously validated arrhythmia
inducibility score for PES in rat hearts (17). Hearts
were then frozen and sectioned for histological
staining with Masson’s trichrome for maximum
contrast and differentiation between scar tissue
and surviving myocardium and for connexin43
(Cx43) immunolabeling.
HISTOLOGY AND HISTOMORPHOMETRY. Infarct size
was quantiﬁed by planimetry using previously vali-
dated methods (18,19). Brieﬂy, endocardial and
epicardial circumferences of the infarct were mea-
sured for each section, and the infarct size was
quantiﬁed as the proportion of endocardial and
epicardial circumferences bounded by the transmural
infarct.
The complexity of IBZ scarring and degree of
heterogeneity of ﬁbrosis was quantiﬁed using an
interface complexity ratio (ICR), deﬁned as the ratio
of the length of interface between ﬁbrosis and
surviving myocardium to the area of ﬁbrosis in
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576that microscopic ﬁeld (Online Appendix, Online
Figure 2). IBZs with greater heterogeneity of
ﬁbrosis have greater ratios, that is, greater interface
between ﬁbrotic and myocardial tissue per unit area
of ﬁbrosis. The interobserver and intraobserver co-
efﬁcients of variation for this method were 12% and
10%, respectively. For each heart, 10-mm slices were
taken at 500-mm intervals across the entire infarct
for staining with 27  5 IBZ microscopic ﬁelds
analyzed per slice. ICR values were then averaged
to give a single mean value and a single SD value,
as a measure of dispersion, per heart. All experi-
ments and analyses were performed blinded to
treatment group.
DATA ANALYSIS AND STATISTICS. Optical mapping
data were analyzed as previously described (15,20,21).
Activation maps were generated, and local con-
duction velocities and vectors were derived using
MATLAB R2010a software (MathWorks, Marlborough,
Massachusetts). Analysis of variance tests were per-
formed to compare means between multiple groups,
and post hoc Tukey test was used if analysis of vari-
ance was signiﬁcant. Student t tests were used
to compare means between 2 groups. A p value
of <0.05 was considered signiﬁcant. All values are
mean  SEM.
RESULTS
CHARACTERIZATION OF CONDUCTION, OPTICAL
ACTION POTENTIALS, AND ARRHYTHMOGENESIS IN
THE CHRONIC HEALED MI MODEL. Sixteen of 24
infarcted rats (67%) and all 4 sham-operated rats
survived the acute surgery. Optical mapping studies
were performed at 4 weeks post-MI. Figure 1A shows
representative activation maps and local conduction
velocity (CV) maps for a chronically infarcted hearts,
and Figure 1B shows representative optical action
potentials from the remote noninfarcted myocar-
dium, the IBZ, and the infarct zone. There was a 49%
reduction in IBZ CV compared with remote non-
infarcted myocardium (34.1  3.2 cm/s vs. 67.6  3.8
cm/s, respectively; p < 0.0001) (Figure 1C). CVs in the
remote myocardium of MI hearts were not different
from the same myocardial region of sham-operated
hearts (73.4  5.8 cm/s). There was increased
dispersion of conduction vector angles in the infarct
zone compared with that in the IBZ and remote
myocardium, demonstrating greater heterogeneity in
directions of activation within the infarct (Figure 1D).
Optical action potential rise times in the infarct
zone and IBZ were prolonged compared with those
recorded at the remote, viable myocardium and thosefrom sham-operated hearts (Figures 1E). Mean action
potential durations were not different among the
infarct zone, the IBZ and remote myocardium, but
there was greater spatial variability of action poten-
tial durations in the infarct zone and IBZ than in
remote myocardium and in sham-operated hearts
(Figure 1F).
Hearts were classiﬁed for arrhythmia susceptibility
based on the PES experiments. All hearts were ranked
by arrhythmia susceptibility and then divided into 2
groups based on the median values. Hearts in the
more arrhythmic (þ) group had values above the
median, and hearts in the less arrhythmic () group
had values below the median. As shown in Figure 1G,
IBZ CVs were signiﬁcantly slower in the PES(þ) hearts
than in the PES() hearts (27.6  3.8 cm/s vs. 39.3 
4.1 cm/s, respectively; p ¼ 0.04), suggesting that IBZ
CV is a determinant of susceptibility to ventricular
arrhythmias on PES in chronic MI hearts.
EFFECTSOF ROTIGAPTIDE TREATMENT ONCONDUCTION,
OPTICALACTION POTENTIALS, ANDARRHYTHMOGENESIS
IN HEALED MI. Of the animals randomized to treat-
ment with either rotigaptide (n ¼ 13) or control
(n ¼ 14), 9 animals from the rotigaptide group and
10 from the control group survived acute MI
surgery (acute mortality in rotigaptide animals: 31%;
29% in control; p ¼ NS). At 4 weeks post-MI, hearts
of animals treated with rotigaptide for the ﬁrst
7 days post-MI had reduced arrhythmia inducibility
at PES than controls, with VT/ventricular ﬁbrillation
(VF) induced in fewer rotigaptide-treated hearts
for any given number of extrastimuli (Figures 2A
and 2B) and a reduction in the arrhythmia induc-
ibility score (rotigaptide: 2.4  0.8; control: 5.0  0.6;
p ¼ 0.02) (Figure 2C). These ﬁndings indicate a dif-
ference in substrate in rotigaptide hearts compared
with that in controls, which rendered hearts more
resistant to PES-induced ventricular arrhythmia.
Figure 3A shows representative activation maps
and optical action potentials for control and rotigap-
tide hearts. Consistent with the demonstration that
IBZ CV is a determinant of arrhythmia susceptibility,
there was a 24% increase in IBZ CV in rotigaptide-
treated hearts compared with untreated post-MI ani-
mals (rotigaptide: 43.1  3.4 cm/s; control: 34.8  2.0
cm/s; p ¼ 0.04) (Figure 3B). There were no differences
in optical action potential rise times and durations
between groups (Figures 3C and 3D).
ROTIGAPTIDE TREATMENT DID NOT ALTER
INFARCT SIZE. Surgical LAD artery ligation produced
transmural infarcts with compensatory hypertrophy of
noninfarcted myocardium, as shown using Masson’s
trichrome-stained biventricular sections in Figure 4A.
FIGURE 1 Electrophysiological and Arrhythmia Determinants of Chronic MI Model
(A) Optical mapping of chronic MI hearts. (B) Representative optical action potentials from remote myocardium, IBZ, and infarct zone. (C) Slower CVs at IBZ compared
with remote myocardium. (D) Conduction vector angles were more heterogeneous in the infarct zone (MI). (E) Prolonged rise times at the infarct zone and IBZ. (F)
Increased dispersion of optical APDs at the infarct zone and IBZ. (C to F) n ¼ 16 for MI hearts, and n ¼ 4 for sham hearts. (G) IBZ CV was slower in PES(þ) hearts (n ¼ 8)
than in PES() hearts (n ¼ 8). *p < 0.05; **p < 0.01; ***p < 0.001. APD ¼ action potential duration; CV ¼ conduction velocity; IBZ ¼ infarct border zone; PES ¼
programmed electrical stimulation.
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577Infarct sizes by planimetry were not different bet-
ween groups (control: 21.0  3.6%; rotigaptide:
20.5  1.7%; p ¼ NS) (Figure 4B), suggesting that
acute GJ enhancement during MI did not grossly alter
infarct size and that this could not account for
the reduced susceptibility to PES arrhythmia in roti-
gaptide hearts.
ROTIGAPTIDE REDUCED HETEROGENEITY OF FIBROSIS
AT THE IBZ. Differences in IBZ morphology andstructural heterogeneity were determined using the
interface complexity ratio (ICR), a measurement of
ﬁbrosis complexity at the IBZ, with greater ratios
representing more complex morphologies (Online
Appendix). Figure 4C shows sample images of IBZ
from control and rotigaptide hearts. Although mean
interface complexity ratios were not signiﬁcantly
different between groups (control: 3.2  0.2; roti-
gaptide: 3.3  0.2; p ¼ NS) (Figure 4D), the degree
FIGURE 2 Reduced Arrhythmia Susceptibility on PES in Rotigaptide-Treated Hearts at 4 Weeks Post-MI
(A, Top) Example of VT/VF induced in a control (CON) heart during PES. (A, Bottom) Example of PES in a rotigaptide (ROT) heart, with no
arrhythmias induced with 3 extrastimuli. (B) Proportions of hearts with VT/VF (duration >1 s) induced with PES. (C) Reduced arrhythmia
inducibility scores for rotigaptide hearts (n ¼ 9) compared with that of control MI hearts (n ¼ 10) (*p < 0.05). Data from sham-operated hearts
(n ¼ 4) presented for comparison. þve ¼ PES positive; ve ¼ PES negative; MI ¼ myocardial infarction; VT/VF ¼ ventricular tachycardia/
ventricular ﬁbrillation; other abbreviations as in Figure 1.
Ng et al. J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 2 , N O . 5 , 2 0 1 6
Peri-MI Rotigaptide Reduces Post-MI Arrhythmias O C T O B E R 2 0 1 6 : 5 7 4 – 8 2
578of heterogeneity of IBZ scarring was reduced after
rotigaptide treatment (SD of ICR values within each
heart, control: 1.4  0.1; rotigaptide: 1.1  0.1;
p ¼ 0.04) (Figure 4E). The reduction in ICR vari-
ability within each heart for the rotigaptide
group points toward more homogeneous patterns of
IBZ scarring, whereas control hearts exhibited a
greater range of IBZ scar morphologies within each
heart.
ROTIGAPTIDE DID NOT ALTER POST-MI CX43
MALDISTRIBUTION. There were no differences in
mean Cx43 lateralization scores between treatment
groups (control: 1.3 0.1, rotigaptide: 1.3 0.1; p¼NS)
(Figures 4F and 4G) or in variability of the Cx43 later-
alization scores (SD of Cx lateralization score withineach heart for control: 0.5  0.1; and for rotigaptide:
0.5  0.1; p ¼ NS).
DISCUSSION
The principal and important ﬁnding of this study is the
proof of concept of a highly novel antiarrhythmic
strategy of modifying infarct healing by short-term
enhancement of GJ function during acute MI, which
modiﬁes the healed arrhythmogenic substrate by
reducing inhomogeneities of ﬁbrosis at the healed
IBZ without gross changes in infarct size, thus reducing
VT/VF inducibility late post-MI. The homogenization
of scarring was associated with a corresponding
improvement in macroscopic CV across the IBZ.
FIGURE 3 Improvement in IBZ CV in Rotigaptide-Treated Hearts
(A) Representative activation maps show conduction slowing at the IBZ of control and rotigaptide hearts and representative IBZ optical APs.
(B) Increase in IBZ CV in rotigaptide-treated hearts (n ¼ 9) compared with untreated control hearts (n ¼ 26). (C and D) No differences
in optical AP rise times and AP duration between groups.
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previous GJ enhancement studies focused on the
direct acute electrophysiological effects of rotigaptide
on conduction (22), rather than this paradigm shift of
modifying the molecular biology of the disease pro-
cess itself with an enduring antiarrhythmic effect
on infarct scar morphology and a reduction in
arrhythmia susceptibility 3 weeks after discontinua-
tion of rotigaptide.
ENHANCEMENT OF GJ COUPLING REDUCED
HETEROGENEITY OF SCARRING AND FIBROSIS AT
THE HEALED IBZ. GJ channels are known to mediate
the spread of small molecules of <1 kDa in molecularweight, including the passage of mediators of cell
death and cell survival during MI (23). During acute
MI, closure of GJ channels occurs (13), thus preventing
the passage of these molecules between cells and
enhancing differential survival between adjacent
cells and clusters of cells because of the heteroge-
neities in local vascular supply, coronary blood ﬂow,
and cellular metabolism (24,25), thus leading to
heterogeneous cell death. In keeping with this
concept, our principal histomorphological ﬁnding of
homogenization of scarring at the IBZ with short-
term rotigaptide treatment, as supported by the
reduced dispersion of ICR values for each heart, is
FIGURE 4 Reduced Heterogeneity of Fibrosis at IBZ of Rotigaptide-Treated Hearts
(A) Representative biventricular slices from the mid-ventricles of MI hearts stained with Masson’s trichrome. (B) No differences are seen in
infarct size between groups. (C) Sample images of the IBZ from control and rotigaptide hearts show complex interaction between ﬁbrosis (blue)
and surviving myocardium (reddish-pink). (D) Mean IBZ ICRs were not different between groups. (E) Rotigaptide reduced the dispersion of ICR
(SD of ICR values within each heart) compared to control MI hearts (*p < 0.05). (F) Cx43 lateralization scoring system. (Left) Normal Cx43
localization at the intercalated discs. (Right) Signiﬁcant lateralization of Cx43 as shown by arrows. (G) Cx43 lateralization scores were not
different between groups. CON n ¼ 10; ROT n ¼ 9. ICR ¼ interface complexity ratio.
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580consistent with possible enhanced gap-junctional
exchange of chemical mediators of cell death and
survival between healthy and dying cells of the IBZ
resulting in more homogeneous patterns of cell
death and infarction (23) (Online Figure 6). Potential
mediators of cell death that can pass through GJchannels include Ca2þ, inositol triphosphate (IP3),
cyclic adenosine monophosphate, and cyclic guano-
sine monophosphate (26), whereas potential “rescue
messengers” that can protect from cell death include
ascorbic acid, reduced glutathione, glucose, and
adenosine triphosphate (27).
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REDUCED LATE POST-MI ARRHYTHMIA SUSCEPTIBILITY.
The reduction in heterogeneity of patterns of ﬁbrosis
and scarring at the healed IBZ of the rotigaptide-
treated hearts was associated with a reduction in
susceptibility to ventricular arrhythmias on PES at
4 weeks post-MI. The observed reduction in hetero-
geneity of IBZ scarringwould be expected to reduce the
occurrence of adjacent areas of fast and slow conduc-
tion and, therefore, reduce the likelihood of
arrhythmia.
Our ﬁnding is consistent with delayed-
enhancement cardiac magnetic resonance studies,
which have found that increased scar heterogeneity
correlated strongly with inducibility of mono-
morphic VT (2) and predicted post-MI mortality (3),
with the zones of greatest tissue heterogeneity
shown to contain critical isthmus sites of scar-
related VT (28). Our proposed strategy for reducing
IBZ scar heterogeneity parallels the interventional
approach of substrate modiﬁcation by catheter
ablation, which has the effect of homogenizing the
infarct scar, thereby reducing or abolishing overall
arrhythmia burden (7,9). Recent clinical studies have
demonstrated that extensive ablation using a com-
bined endocardial and epicardial approach to ho-
mogenize infarct scars can improve freedom from
arrhythmia (7), whereas the similar but less exten-
sive ablation approach of homogenizing scar tissue
by ablating conducting channels has also been
shown to reduce VT recurrence (9). Our strategy is
also supported by recent experiments demonstrating
that the homogenization of ventricular scar by
the application of collagenase can create a less
arrhythmic substrate (8).
IMPROVEMENT IN CONDUCTION VELOCITY AT THE
HEALED IBZ OF ROTIGAPTIDE-TREATED HEARTS.
Improvement in macroscopic CV across the IBZ in
rotigaptide-treated hearts is consistent with the
ﬁnding of reduced scar heterogeneity in those hearts,
which would be expected to reduce the tortuosity and
conduction path lengths across the IBZ, as described
above (5). These ﬁndings further support a central
role for the IBZ in post-MI arrhythmia and lend
weight to the notion that treatments that alter IBZ
scar morphology can alter post-MI arrhythmia
susceptibility.
ROTIGAPTIDE DID NOT SIGNIFICANTLY ALTER
INFARCT SIZE. There were no gross differences in
infarct size between control and rotigaptide. Previous
studies looking speciﬁcally at the effects of GJ en-
hancement on infarct size have produced conﬂictingresults, with a study demonstrating a minor increase
in infarct size (11), whereas studies using the phar-
macological GJ modulators rotigaptide and danegap-
tide have shown minor reductions in infarct size
(10,12). These disparities may reﬂect differences in
animal models and of timing and duration of
enhancement of coupling, as well as differences in
methods of measuring infarct size. In any case, any
differences in scar size are at most minimal, and
although too small to signiﬁcantly salvage mechani-
cal contractile function, our ﬁndings indicate that
even subtle scar homogenization signiﬁcantly re-
duces arrhythmogenesis with the potential for clin-
ical impact.
STUDY LIMITATIONS. Optical recordings of trans-
membrane potential were limited to a depth of
several cells at the subepicardium, which meant we
were unable to precisely map the location of re-
entrant circuits of the induced arrhythmias and
had to extrapolate the electrophysiology of deeper
myocardial layers from subepicardial data, although
the use of optical mapping to interrogate the elec-
trophysiology of the IBZ has previously been vali-
dated (29).
Although it was not possible to measure directly
the effects of rotigaptide on GJ coupling during
acute MI in the in vivo cohort, we conﬁrmed in
parallel ex vivo studies that rotigaptide has the
expected effects on conduction velocity and Cx43
phosphorylation consistent with GJ enhancement in
acute ischemia and acute metabolic stress (Online
Appendix).
CONCLUSIONS
Enhancement of GJ coupling for a limited duration
only during the acute phase of MI can reduce in-
homogeneities of ﬁbrosis in the healed IBZ while
reducing late susceptibility to PES-induced ventri-
cular tachyarrhythmias at the chronic healed
infarct phase and may represent a novel clinically-
applicable therapeutic strategy to reduce late post-
MI ventricular arrhythmias.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Increased heterogeneity of myocardial scarring after MI
is associated with greater arrhythmia susceptibility.
Approaches to homogenize scar, such as ablation, have
demonstrated anti-arrhythmic beneﬁt. Here, we propose
a novel pharmacological strategy to homogenize scar by
peri-MI GJ enhancement.
TRANSLATIONAL OUTLOOK: Enhancement of GJ
coupling during acute MI may represent a novel, clinically
applicable therapeutic strategy to reduce heterogeneities
of scarring at the IBZ and reduce post-MI ventricular
arrhythmias. In our proof-of-concept study, a loading dose
of rotigaptide was administered immediately pre-MI to
allow for therapeutic concentrations at the time of MI.
Further experiments are required to determine if short-
term GJ enhancement commencing after MI onset or
chronic GJ enhancement pre-MI confer similar beneﬁcial
effects before moving into clinical trials. Furthermore,
studies to determine the safety and side-effect proﬁle of
limited-duration and chronic GJ enhancement in humans
are also required prior to clinical translation.
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APPENDIX For an expanded Methods and
Materials and Results sections, as well as sup-
plemental ﬁgures, please see the online version
of this article.
